Q1 Earnings Estimate for Exelixis Issued By Leerink Partnrs

Exelixis, Inc. (NASDAQ:EXEL) – Leerink Partnrs lifted their Q1 2025 earnings estimates for Exelixis in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will post earnings of $0.36 per share for the quarter, up from their previous forecast of $0.35. The consensus estimate for Exelixis’ current full-year earnings is $2.04 per share. Leerink Partnrs also issued estimates for Exelixis’ Q2 2025 earnings at $0.50 EPS, Q4 2025 earnings at $0.68 EPS and FY2025 earnings at $2.15 EPS.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%.

A number of other equities analysts have also recently weighed in on the company. Royal Bank of Canada upped their price target on Exelixis from $38.00 to $40.00 and gave the stock an “outperform” rating in a report on Thursday, March 13th. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Exelixis in a report on Thursday. BMO Capital Markets downgraded shares of Exelixis from an “outperform” rating to a “market perform” rating and boosted their price objective for the company from $36.00 to $40.00 in a research report on Friday, December 20th. Finally, Stifel Nicolaus increased their price target on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of “Moderate Buy” and an average price target of $37.59.

Exelixis Price Performance

Shares of EXEL opened at $36.70 on Friday. Exelixis has a 12 month low of $20.14 and a 12 month high of $40.02. The stock’s 50-day moving average is $35.71 and its two-hundred day moving average is $33.22. The stock has a market cap of $10.27 billion, a PE ratio of 20.73, a P/E/G ratio of 1.13 and a beta of 0.57.

Institutional Investors Weigh In On Exelixis

A number of institutional investors and hedge funds have recently made changes to their positions in the company. MassMutual Private Wealth & Trust FSB raised its position in shares of Exelixis by 18.1% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 290 shares during the last quarter. Balyasny Asset Management L.P. raised its position in shares of Exelixis by 1.9% in the 4th quarter. Balyasny Asset Management L.P. now owns 17,203 shares of the biotechnology company’s stock valued at $573,000 after acquiring an additional 317 shares during the period. Steward Partners Investment Advisory LLC raised its position in shares of Exelixis by 4.9% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,050 shares of the biotechnology company’s stock valued at $235,000 after acquiring an additional 330 shares during the period. Oregon Public Employees Retirement Fund boosted its position in shares of Exelixis by 0.6% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 58,159 shares of the biotechnology company’s stock worth $1,937,000 after purchasing an additional 354 shares in the last quarter. Finally, Principal Securities Inc. lifted its holdings in Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 373 shares in the last quarter. Institutional investors own 85.27% of the company’s stock.

Insiders Place Their Bets

In other news, Director Bob Oliver sold 18,647 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total transaction of $694,600.75. Following the sale, the director now owns 33,514 shares in the company, valued at approximately $1,248,396.50. This represents a 35.75 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the transaction, the executive vice president now directly owns 303,310 shares of the company’s stock, valued at $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock worth $5,177,234 over the last 90 days. Corporate insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.